In this episode, we dive deep into how rising U.S. tariffs on pharmaceutical imports—from APIs and drug intermediates to packaging and manufacturing equipment—are transforming the industry. With 20–25% duties on imports from China and India, pharma manufacturers are facing surging costs, disrupted supply chains, and longer production timelines. We unpack the sector-wise impact on generics, biologics, vaccines, and CMOs, and explore how companies are responding through nearshoring, regulatory navigation, and data-driven decision-making. Discover how market research is evolving from a background tool to a front-line defense in safeguarding resilience, cost-efficiency, and therapeutic continuity.